Vitrakvi
FDA Grants Full Approval to Bayer's Vitrakvi in NTRK-Positive Solid Tumors
The 2018 accelerated approval of Vitrakvi was converted to full approval based on results from three trials in adult and pediatric patients.
Tissue-Agnostic Trial Shows Frontline Vitrakvi Benefit in NTRK-Positive Pediatric Solid Tumors
In the Phase II ADVL1823 study, researchers evaluated Vitrakvi in children with newly diagnosed IFS and other solid tumors with NTRK fusions.
In Brief This Week: Proteomics International, Children's Hospital of Philadelphia, Bayer
News items for the week of Nov. 20, 2023.